The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Biotech’s rise in China, Amgen’s future in Alzheimer’s, & noticias de adquisición

By Damian Garde

The READOUT
The Readout

Sarepta’s respectful secrecy & Gilead’s patent offense

By Damian Garde

The READOUT
The Readout

Why FDA blasted Novartis & Sarepta’s future past

By Damian Garde

The READOUT
The Readout

AveXis exec breaks his silence & Sarepta gets a rejection

By Damian Garde

The READOUT
The Readout

Sarepta’s up for approval & Northwest’s CEO collects

By Meghana Keshavan

The READOUT
The Readout

Your guide to tumor-fighting BiTEs & the new normal in cancer drug approvals

By Damian Garde

The READOUT
The Readout

Sarepta’s delay & Novartis’ housecleaning

By Damian Garde

The READOUT
The Readout

Why the FDA snapped at Novartis & how a unicorn loses its horn

By Damian Garde

The READOUT
The Readout

Sorting out Sarepta & biotech lands in Shanghai

By Damian Garde

The READOUT
The Readout

Biotech’s credibility issue & Amgen files suit (again)

By Meghana Keshavan

The READOUT
The Readout

Amarin’s twist of fate & Novartis’ fallout

By Damian Garde

The READOUT
The Readout

Novartis’ scandal management & Trump’s long awaited pricing speech

By Damian Garde

The READOUT
The Readout

A Novartis crisis & a CEO announcement at Editas

By Damian Garde

The READOUT
The Readout

Pay-to-play clinical trials & Regeneron’s growth story

By Damian Garde

The READOUT
The Readout

Validation for liquid biopsy & Allogene’s hot recruit

By Damian Garde

The READOUT
The Readout

PhRMA’s top lobbyist on the way out & an emotional ICER meeting

By Damian Garde

The READOUT
The Readout

Biotech VC parties on & drug importation isn’t what it seems

By Damian Garde

The READOUT
The Readout

Winners and losers of earnings season & UniQure’s strange summer

By Damian Garde

The READOUT
The Readout

Pfizer-Mylan’s early reviews & the latest CRISPR progress

By Damian Garde

The READOUT
The Readout

Escalating pricing politics & burning questions, revisited

By Meghana Keshavan

The READOUT
The Readout

The latest IPO craze & Vertex’s new CEO

By Damian Garde

The READOUT
The Readout

ICER under fire & Sage’s big swing

By Damian Garde

The READOUT
The Readout

FDA tea leaves & pricing bill fallout

By Damian Garde

The READOUT
The Readout

Acadia’s fallible strategy & McCaskill’s enduring ambition

By Damian Garde

The READOUT
The Readout

The CRISPR fight takes a turn & a censuring Indian pharma

By Damian Garde

The Readout

In the room with Elon Musk & your Alzheimer’s questions

By Damian Garde

The READOUT
The Readout

Early reviews for Elon Musk & PhRMA on the hill

By Damian Garde

The READOUT
The Readout

Our pricing policy tracker & the future of Neuralink

By Damian Garde

The READOUT
The Readout

How pharma thwarted Washington & Elon Musk’s brain computers

By Damian Garde

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy